Tagrisso (osimertinib) is not currently approved for the treatment of glioblastoma [1]. The drug is approved for certain types of non-small cell lung cancer (NSCLC) that have a specific genetic mutation (EGFR-TKI-resistant T790M mutation) [1].
What types of cancer is Tagrisso approved for?
Tagrisso is indicated for the treatment of adult patients with metastatic EGFR-mutated NSCLC whose disease has progressed on or after a prior EGFR-TKI therapy [1]. It is also approved for the adjuvant treatment of adult patients with NSCLC whose tumors have an EGFR exon 19 deletion or EGFR exon 21 (L858R) substitution, after surgical resection [1].
Is Tagrisso being investigated for glioblastoma?
Research into the potential use of Tagrisso for glioblastoma is ongoing. Clinical trials are evaluating its efficacy and safety in this patient population, but results are not yet available to support approval [2].
What are the current treatment options for glioblastoma?
Standard treatments for glioblastoma typically include surgery, radiation therapy, and chemotherapy [3]. The specific treatment plan can vary depending on factors such as the patient's age, overall health, and the characteristics of the tumor [3].
How do EGFR mutations relate to glioblastoma?
While EGFR mutations are well-established drivers in some lung cancers, their role and prevalence in glioblastoma are complex and less consistently linked to treatment response with EGFR inhibitors compared to NSCLC [4]. Research is exploring the specific genomic landscape of glioblastoma to identify potential therapeutic targets, including those related to EGFR signaling pathways [4].
When might Tagrisso be approved for glioblastoma?
Any potential approval of Tagrisso for glioblastoma would depend on the successful outcome of ongoing clinical trials and subsequent review by regulatory agencies like the U.S. Food and Drug Administration (FDA) [2]. There is no set timeline for these decisions.
What are the side effects of Tagrisso?
Common side effects of Tagrisso include diarrhea, rash, dry skin, and stomatitis [1]. More serious side effects can occur, and patients should discuss potential risks with their healthcare provider [1].
Sources:
[1] https://www.drugpatentwatch.com/drug/osimertinib/112012
[2] https://clinicaltrials.gov/ct2/show/NCT03555402
[3] https://www.cancer.gov/types/brain/patient/adult-glioblastoma-treatment-pdq
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4325902/